Estados Unidos · Plataformas y datos · MarketBeat
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Resumen detallado
Aquestive Therapeutics (NASDAQ:AQST) is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference. The company’s lead product candidate, An
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)




